Capsid containing virus like particle vaccine against Zika virus made from a stable cell line

Garg, Himanshu; Mehmetoglu-Gurbuz, Tugba; Ruddy, Gregory M.; Joshi, Anjali

doi:10.1016/j.vaccine.2019.09.093

Cited by 16 publications

(21 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bicistronic vector expressing flaviviral CprME and Zika NS2B3 produces Capsid protein containing VLPs. The presence of Capsid protein in a flaviviral vaccine can provide an additional immunogen and higher neutralizing antibody titers as seen in our Zika VLP vaccine studies 13,14 . In order to produce CprME VLPs, NS2B3 expression can be achieved either in trans as in Fig.…”

Section: Reporter Virus Particle Based Neutralization Assay Is Sensitmentioning

confidence: 77%

“…While a number of arboviral VLPs have been developed including some for JEV and DENV, most of these studies utilize prME expression and the particles lack Capsid protein 15 . The inclusion of Capsid protein in all of our VLP preps provides an additional antigen and better immunogenicity as evident from our Zika studies 13,14 . Furthermore, previous studies on arboviral VLPs including CHIKV have been conducted in monovalent forms and there is no study on whether a multivalent VLP vaccine against related arboviruses would provide effective immunity 22 .…”

Section: Discussionmentioning

confidence: 89%

“…A VLP vaccine against CHIKV has shown efficacy in animal models and has now progressed to human trials 22 . Similarly a ZIKV VLP vaccine has been tested in our lab in small animal www.nature.com/scientificreports www.nature.com/scientificreports/ model and shown to generate high titer neutralizing antibodies that protect against live virus challenge 14 . While a number of arboviral VLPs have been developed including some for JEV and DENV, most of these studies utilize prME expression and the particles lack Capsid protein 15 .…”

Section: Discussionmentioning

confidence: 99%

“…4C) for future analysis. The ZIKV E2 cell line has been described and characterized before 14 . Using this strategy we were able to find high VLP secreting single cell clones for JEV, YFV, ZIKV and CHIKV.…”

Section: Generation Of Stable Cell Lines Producing Zikv Yfv Jev Andmentioning

confidence: 99%

“…Previously, we developed a VLP vaccine candidate for Zika virus and found that the immunogenicity of Capsid protein containing VLPs (CprME) was better than prME VLPs 13 . Furthermore, the use of stable cell lines to generate VLPs provides a much needed platform for the advancement and commercialization of this technology 14 . Besides being safe and efficacious, VLP vaccines also provide the added advantage of multivalency by combining closely related different VLPs in desired concentrations into a single formulation 15 .…”

mentioning

confidence: 99%

See 4 more Smart Citations

Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus

Garg

Mehmetoglu-Gurbuz

Joshi

2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

Mosquito borne viral diseases are an emerging threat as evident from the recent outbreak of Zika virus (ZiKV) as well as repeated outbreaks of chikungunya (cHiKV), Yellow fever (YfV) and Japanese encephalitis (JEV) virus in different geographical regions. These four arboviruses are endemic in overlapping regions due to the co-prevalence of the transmitting mosquito vector species Aedes and Culex. Thus, a multivalent vaccine that targets all four viruses would be of benefit to regions of the world where these diseases are endemic. We developed a potential Virus Like Particle (VLP) based multivalent vaccine candidate to target these diseases by using stable cell lines that continuously secrete VLps in the culture supernatants. Moreover, inclusion of Capsid in the VLPs provides an additional viral protein leading to an enhanced immune response as evident from our previous studies with ZIKV. Immunization of Balb/c mice with different combinations of Capsid protein containing VLPs either as monovalent, bivalent or tetravalent formulation resulted in generation of high levels of neutralizing antibodies. Interestingly, the potential tetravalent VLP vaccine candidate provided strong neutralizing antibody titers against all four viruses. The 293 T stable cell lines secreting VLPs were adapted to grow in suspension cultures to facilitate vaccine scale up. Our stable cell lines secreting individual VLPs provide a flexible yet scalable platform conveniently adaptable to different geographical regions as per the need. Further studies in appropriate animal models will be needed to define the efficacy of the multivalent vaccine candidate to protect against lethal virus challenge.Arthropod borne viruses are a group of pathogens that are transmitted in the human population via the bite of arthropods including mosquitoes, flies and ticks. Recent increase in arboviral epidemics in the human population has been attributed to various factors including urbanization and geographical expansion of both the host and vectors for these diseases 1,2 . Amongst these arboviral diseases, Chikungunya (CHIKV), Japanese Encephalitis (JEV), Yellow Fever (YFV) and Zika virus (ZIKV) have expanded from isolated outbreaks in endemic areas to large scale epidemics affecting multiple continents 3,4 . The recent outbreaks of ZIKV 5 and previous outbreaks of CHIKV 6 are indications that these viruses will continue to plague the human population putting millions at risk and adding a significant burden on the healthcare system.The World Health Organization lists Dengue virus (DENV) as the most common mosquito-borne viral disease with CHIKV, YFV and JEV as other arboviruses being endemic in various parts of the world. The majority of human population that resides in the tropical and subtropical regions of the world is at risk for at least one of these arboviral infections. These pathogens are transmitted via vectors that are found in overlapping geographical regions; Aedes sp in the case of CHIKV, YFV and ZIKV and Culex sp in the case of JEV 2 . Furthermore, ...

show abstract

Section: Reporter Virus Particle Based Neutralization Assay Is Sensitmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Generation Of Stable Cell Lines Producing Zikv Yfv Jev Andmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus

Garg

Mehmetoglu-Gurbuz

Joshi

2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

Perspectives on the Technological Aspects and Biomedical Applications of Virus‐Like Particles/Nanoparticles in Reproductive Biology: Insights on the Medicinal and Toxicological Outlook

Chandrasekar

Singh

Maharjan

et al. 2022

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Increasing data on the infection indicate that maternal infections are severe. Under the realms of vaccine development, virus‐like particles (VLP)/nanoparticles (NPs) hold the promise of targeted control of therapeutics transfer across the placental barrier with the potential to trigger innate immune responses. Though the placenta is known to act as a barrier against exogenous materials, viruses exploit the transport systems and overcome the barrier properties. VLPs can be strategically designed to obtain the necessary mechanisms for navigation across the placenta and immune response. However, several knowledge gaps on the chemical, viral transmission strategies and the host defense response exist owing to the highly dynamic etiology of the placental barrier. This further complicates the toxicological analysis of the developed therapeutics. Herein, placental physiology and functions are discussed in significance with chemical toxicology, viral infections, and the host defense. Further, the promising applications of VLPs and perspective on their design to overcome the placental gatekeeper to gain the necessary immune response or therapy are provided. Finally, a holistic approach to various bioengineering models for studying chemical toxicants, viral infections, and effects of VLPs is provided to facilitate better translation of these VLPs to clinical applications.

show abstract

Clinical neurological spectrum of adult and congenital ZIKV infection: An overview of virology, pathogenesis, and management

Lam

Xuan

Tambyah

et al. 2021

Zika Virus Impact, Diagnosis, Control, and Models

View full text Add to dashboard Cite

Capsid containing virus like particle vaccine against Zika virus made from a stable cell line

Cited by 16 publications

References 34 publications

Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus

Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus

Perspectives on the Technological Aspects and Biomedical Applications of Virus‐Like Particles/Nanoparticles in Reproductive Biology: Insights on the Medicinal and Toxicological Outlook

Clinical neurological spectrum of adult and congenital ZIKV infection: An overview of virology, pathogenesis, and management

Contact Info

Product

Resources

About